A Prospective Epidemiological Study Evaluating Occurrences of Influenza-like Illness

Active, not recruiting

• Conditions: Influenza

• Registration Number: NCT06779981
• Lead Sponsor: Osivax

Brief Summary

This prospective epidemiological cohort study is being conducted in order to generate epidemiological data in support of Osivax's clinical development of a broad-spectrum influenza vaccine based upon the internal influenza nucleoprotein (NP), i.e., OVX836.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-12-13
• Status Verified: 2025-01
• Study First Submitted: 2025-01-14
• Study First Submitted QC: 2025-01-14
• Last Update Submitted: 2025-01-16
• Study First Posted: 2025-01-17
• Last Update Posted: 2025-01-20
• Primary Completion: 2025-06
• Study Completion: 2025-06

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 119

Inclusion Criteria

1. Written informed consent.
2. Healthy male or female participants, as determined by medical history and medical examination (as needed).
3. Between the ages of 20 and 64 years, inclusive.
4. Reliable and willing to make themselves available for the duration of the study, and willing and able to follow study procedures.
5. Ability and technical possibility for completing an eDiary.

Exclusion Criteria

1. Subjects with a body mass index (BMI) ≤18 kg/m² or ≥35 kg/m²
2. Previous influenza vaccination within 6 months before the day of enrollment or planned to receive during the study duration.
3. Previous vaccination with an mRNA-based influenza vaccine including NP in its composition.
4. Previous administration of OVX836.
5. Pregnant or lactating woman.
6. Females planning to become pregnant or planning to discontinue contraceptive precautions until the end of the trial. Women of childbearing potential (WOCBP) should have appropriate contraceptive methods in place for 2 months before enrolment. Appropriate contraceptive methods are to be maintained until the end of the trial. Please also refer to Appendix A.
7. Past or current history of significant autoimmune diseases, as judged by the Investigator.
8. Current history of uncontrolled medical illness such as diabetes, hypertension, heart, renal or hepatic diseases.
9. Known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).
10. Planned administration of any investigational or non-registered product during the entire study period.
11. History of receiving blood, blood components, or immunoglobulins within 3 months prior to the first study visit or planned to receive such product during the whole study period.
12. Behavioral or cognitive impairment, or psychiatric disease that, in the opinion of the Investigator, may interfere with the subject's ability to participate in the study.
13. History of alcohol or drug abuse that ceased less than 6 months before enrolment, current alcohol or drug abuse according to the Investigator's judgement), smoking habit of more than 10 cigarettes/day, or current vaping (nicotine consumption corresponding to more than 10 cigarettes/day).
14. Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months before the study vaccine administration. For corticosteroids, this will mean prednisone equivalent ≥20 mg/day. Inhaled, topical and intra-articular steroids are allowed.
15. Individuals with a history of any illness that, in the opinion of the Investigator, could potentially interfere with the results of the study or pose additional risk to the subjects by participating in the study.
16. Sponsor employees or Investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted, including children of newly composed families.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number and percentage of participants reporting ILI episodes (overall, laboratory confirmed or not), during the influenza season and during the whole study.	Through study completion, an average of 6 months.
Number and percentage of participants presenting RT-PCR confirmed influenza A or B cases, during the influenza season and during the whole study.	Through study completion, an average of 6 months.
Number and percentage of participants presenting RT-PCR confirmed SARS-CoV-2 cases, during the influenza season and during the whole study.	Through study completion, an average of 6 months.

Trial Locations

Locations (1)

Centre for Vaccinology (CEVAC); 🇧🇪 Ghent, Belgium